Ketamine and rapid-acting antidepressants: A new era in the battle against depression and suicide.

F1000Research

Volumn 7, Issue , 2018, Pages

  Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; Ketamine; MTOR; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; AV 101; BRAIN DERIVED NEUROTROPHIC FACTOR; BREXANOLONE; ESKETAMINE; GLUTAMATE RECEPTOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RAPASTINEL; SAGE 217; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; DEPRESSION; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG TARGETING; HUMAN; LONG TERM POTENTIATION; METABOLITE; NERVE CELL PLASTICITY; NONHUMAN; POSTNATAL DEPRESSION; PREFRONTAL CORTEX; REVIEW; STEREOISOMERISM; STRESS; SUICIDE;

EID: 85047819140     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/f1000research.14344.1     Document Type: Review

References (75)

1. WHO: WHO | Depression [Internet].Depression.2017.
2. Kessler RC Chiu WT Demler O: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-27. 15939839 10.1001/archpsyc.62.6.617 2847357 F1000 Recommendation
3. Kessler RC: The costs of depression. Psychiatr Clin North Am. 2012;35(1):1-14. 22370487 10.1016/j.psc.2011.11.005 3292769
4. Murray CJ Atkinson C Bhalla K: The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591-608. 23842577 10.1001/jama.2013.13805 5436627
5. Trivedi MH Rush AJ Wisniewski SR: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. 16390886 10.1176/appi.ajp.163.1.28 F1000 Recommendation
6. Curtin SC Warner M Hedegaard H: Increase in Suicide in the United States, 1999-2014. NCHS Data Brief. 2016; (241):1-8. 27111185
7. National Violent Death Reporting System. CDC.2015. Reference Source
8. Berman RM Cappiello A Anand A: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4. 10686270 10.1016/S0006-3223(99)00230-9
9. Zarate CA Jr Singh JB Carlson PJ: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64. 16894061 10.1001/archpsyc.63.8.856 F1000 Recommendation
10. Wilkinson ST Ballard ED Bloch MH: The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150-8. 28969441 10.1176/appi.ajp.2017.17040472 5794524 F1000 Recommendation
11. Sanacora G Frye MA McDonald W: A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405. 28249076 10.1001/jamapsychiatry.2017.0080
12. Wilkinson ST Toprak M Turner MS: A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. Am J Psychiatry. 2017;174(7):695-6. 28669202 10.1176/appi.ajp.2017.17020239 5549850 F1000 Recommendation
13. Newport DJ Carpenter LL McDonald WM: Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015;172(10):950-66. 26423481 10.1176/appi.ajp.2015.15040465
14. Duman RS Aghajanian GK Sanacora G: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238-49. 26937618 10.1038/nm.4050 5405628
15. McEwen BS Eiland L Hunter RG: Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. Neuropharmacology. 2012;62(1):3-12. 21807003 10.1016/j.neuropharm.2011.07.014 3196296
16. Morrison JH Baxter MG: The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci. 2012;13(4):240-50. 22395804 10.1038/nrn3200 3592200
17. Kang HJ Voleti B Hajszan T: Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med. 2012;18(9):1413-7. 22885997 10.1038/nm.2886 3491115 F1000 Recommendation
18. Li N Lee B Liu RJ: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-64. 20724638 10.1126/science.1190287 3116441 F1000 Recommendation
19. Li N Liu RJ Dwyer JM: Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69(8):754-61. 21292242 10.1016/j.biopsych.2010.12.015 3068225 F1000 Recommendation
20. Duman RS Aghajanian GK: Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72. 23042884 10.1126/science.1222939 4424898 F1000 Recommendation
21. Yang Y Cui Y Sang K: Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554(7692):317-22. 29446381 10.1038/nature25509 F1000 Recommendation
22. Moghaddam B Adams B Verma A: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921-7. 9092613 10.1523/JNEUROSCI.17-08-02921.1997
23. Widman AJ McMahon LL: Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proc Natl Acad Sci U S A. 2018;115(13):E3007-E3016. 29531088 10.1073/pnas.1718883115 5879689 F1000 Recommendation
24. Autry AE Adachi M Nosyreva E: NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91-5. 21677641 10.1038/nature10130 3172695 F1000 Recommendation
25. Liu RJ Lee FS Li XY: Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012;71(11):996-1005. 22036038 10.1016/j.biopsych.2011.09.030 3290730
26. Lepack AE Fuchikami M Dwyer JM: BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18(1): pii: pyu033. 25539510 10.1093/ijnp/pyu033 4368871
27. Kato T Fogaça MV Deyama S: BDNF release and signaling are required for the antidepressant actions of GLYX-13. Mol Psychiatry. 2017. 29203848 10.1038/mp.2017.220
28. Liu RJ Fuchikami M Dwyer JM: GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. 2013;38(11):2268-77. 23680942 10.1038/npp.2013.128 3773678
29. Dwyer JM Lepack AE Duman RS: mTOR activation is required for the antidepressant effects of mGluR 2/3 blockade. Int J Neuropsychopharmacol. 2012;15(4):429-34. 22114864 10.1017/S1461145711001702 3580765
30. Yang C Li WY Yu HY: Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex. J Biomed Biotechnol. 2012;2012: 175619. 22577289 10.1155/2012/175619 3336144
31. Carrier N Kabbaj M: Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology. 2013;70:27-34. 23337256 10.1016/j.neuropharm.2012.12.009
32. Miller OH Yang L Wang CC: GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife. 2014;3:e03581. 25340958 10.7554/eLife.03581 4270067 F1000 Recommendation
33. Paul RK Singh NS Khadeer M: ( R,S)-Ketamine metabolites ( R,S)-norketamine and ( 2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology. 2014;121(1):149-59. 24936922 10.1097/ALN.0000000000000285 4061505
34. Zhou W Wang N Yang C: Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014;29(7):419-23. 24321772 10.1016/j.eurpsy.2013.10.005
35. Chiu CT Scheuing L Liu G: The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol. 2014;18(6): pii: pyu102. 25548109 10.1093/ijnp/pyu102 4438544
36. Pazini FL Cunha MP Rosa JM: Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. Mol Neurobiol. 2016;53(10):6818-34. 26660117 10.1007/s12035-015-9580-9
37. Zhang YH Zhang J Song JN: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia. Oncotarget. 2016;7(27):40939-52. 27340771 10.18632/oncotarget.10172 5173033
38. Wang CQ Ye Y Chen F: Posttraumatic administration of a sub-anesthetic dose of ketamine exerts neuroprotection via attenuating inflammation and autophagy. Neuroscience. 2017;343:30-8. 27916727 10.1016/j.neuroscience.2016.11.029
39. Rame M Caudal D Schenker E: Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation. PLoS One. 2017;12(5):e0177036. 28472198 10.1371/journal.pone.0177036 5417651
40. Harraz MM Tyagi R Cortés P: Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry. 2016;21(3):313-9. 26782056 10.1038/mp.2015.211 4830355 F1000 Recommendation
41. Liu RJ Duman C Kato T: GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine. Neuropsychopharmacology. 2017;42(6):1231-42. 27634355 10.1038/npp.2016.202 5437877 F1000 Recommendation
42. Yang C Ren Q Qu Y: Mechanistic Target of Rapamycin-Independent Antidepressant Effects of ( R)-Ketamine in a Social Defeat Stress Model. Biol Psychiatry. 2018;83(1):18-28. 28651788 10.1016/j.biopsych.2017.05.016 F1000 Recommendation
43. Popp S Behl B Joshi JJ: In search of the mechanisms of ketamine's antidepressant effects: How robust is the evidence behind the mTor activation hypothesis [version 1; referees: 1 approved, 1 approved with reservations] F1000Res. 2016;5:634. 10.12688/f1000research.8236.1 F1000 Recommendation
44. Sanacora G Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40(5):1307. 25767082 10.1038/npp.2014.338 4367478
45. Haroon E Miller AH: Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. Curr Top Behav Neurosci. 2017;31:173-98. 27830574 10.1007/7854_2016_40 F1000 Recommendation
46. Sanacora G Johnson MR Khan A: Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017;42(4):844-53. 27681442 10.1038/npp.2016.224 5312066
47. Zarate CA Jr Singh JB Quiroz JA: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-5. 16390905 10.1176/appi.ajp.163.1.153
48. Sanacora G Smith MA Pathak S: Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19(9):978-85. 24126931 10.1038/mp.2013.130 4195977
49. Yang C Shirayama Y Zhang JC: R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632. 26327690 10.1038/tp.2015.136 5068814
50. Zanos P Moaddel R Morris PJ: NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481-6. 27144355 10.1038/nature17998 4922311 F1000 Recommendation
51. Fukumoto K kato T Li X-Y: Role of BDNF/mTORC1 signaling in the long-lasting antidepressant effects of (2R,6R)-hydroxynorketamine. American College of Neuropsychopharmacology. 2017
52. Yang C Qu Y Abe M: ( R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2 R,6 R)-Hydroxynorketamine. Biol Psychiatry. 2017;82(5):e43-e44. 28104224 10.1016/j.biopsych.2016.12.020 F1000 Recommendation
53. Shirayama Y Hashimoto K: Lack of Antidepressant Effects of (2 R,6 R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with ( R)-Ketamine. Int J Neuropsychopharmacol. 2018;21(1):84-8. 29155993 10.1093/ijnp/pyx108 5795355 F1000 Recommendation
54. Suzuki K Nosyreva E Hunt KW: Effects of a ketamine metabolite on synaptic NMDAR function. Nature. 2017;546(7659):E1-E3. 28640258 10.1038/nature22084 F1000 Recommendation
55. Preskorn SH Baker B Kolluri S: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631-7. 19011431 10.1097/JCP.0b013e31818a6cea
56. Ibrahim L Diaz Granados N Jolkovsky L: A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32(4):551-7. 22722512 10.1097/JCP.0b013e31825d70d6 3438886
57. Maeng S Zarate CA Jr Du J: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349-52. 17643398 10.1016/j.biopsych.2007.05.028
58. Moskal JR Burgdorf JS Stanton PK: The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant. Curr Neuropharmacol. 2017;15(1):47-56. 26997507 10.2174/1570159X14666160321122703 5327451 F1000 Recommendation
59. Burgdorf J Zhang XL Nicholson KL: GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013;38(5):729-42. 23303054 10.1038/npp.2012.246 3671991
60. Yang B Zhang JC Han M: Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 2016;233(19-20):3647-57. 27488193 10.1007/s00213-016-4399-2 5021744 F1000 Recommendation
61. Preskorn S Macaluso M Mehra DO: Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21(2):140-9. 25782764 10.1097/01.pra.0000462606.17725.93
62. Garay RP Zarate CA Jr Charpeaud T: Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17(6):593-609. 28092469 10.1080/14737175.2017.1283217 5418088 F1000 Recommendation
63. Dwyer JM Lepack AE Duman RS: mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry. 2013;1(1):15. 25408908 10.1186/2049-9256-1-15 4224009
64. Koike H Iijima M Chaki S: Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology. 2011;61(8):1419-23. 21903115 10.1016/j.neuropharm.2011.08.034
65. Furey ML Drevets WC: Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121-9. 17015814 10.1001/archpsyc.63.10.1121 3250308
66. Drevets WC Furey ML: Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432-8. 20074703 10.1016/j.biopsych.2009.11.021 3264395
67. Voleti B Navarria A Liu RJ: Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74(10):742-9. 23751205 10.1016/j.biopsych.2013.04.025 3773272
68. Ghosal S Bang E Yue W: Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine. Biol Psychiatry. 2018;83(1):29-37. 28751069 10.1016/j.biopsych.2017.06.017 5705490
69. Wohleb ES Wu M Gerhard DM: GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest. 2016;126(7):2482-94. 27270172 10.1172/JCI85033 4922686
70. Fischell J Van Dyke AM Kvarta MD: Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABA A Receptors. Neuropsychopharmacology. 2015;40(11):2499-509. 25900119 10.1038/npp.2015.112 4569955
71. Zanos P Nelson ME Highland JN: A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. eNeuro. 2017;4(1): pii: ENEURO.0285-16.2017. 28275719 10.1523/ENEURO.0285-16.2017 5334634
72. Efeyan A Comb WC Sabatini DM: Nutrient-sensing mechanisms and pathways. Nature. 2015;517(7534):302-10. 25592535 10.1038/nature14190 4313349
73. Maguire J Mody I: GABA AR plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008;59(2):207-13. 18667149 10.1016/j.neuron.2008.06.019 2875248
74. Kanes S Colquhoun H Gunduz-Bruce H: Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390(10093):480-9. 28619476 10.1016/S0140-6736(17)31264-3
75. Kanes SJ Colquhoun H Doherty J: Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol. 2017;32(2):e2576. 28370307 10.1002/hup.2576 5396368